TABLE 1.

Baseline characteristics of patients with ICMP and SNLV.

	SNLV (N = 12)	ICMP (N = 10)	p-value
Age (years)	62 (19)	69 (12)	0.098
Male (n, %)	5 (41)	10 (100)	0.005*
EF (%)	60 (7.5)	35 (25)	<0.001*
LVEDD (cm)	4.75 (0.55)	5.6 (0.9)	0.002*
VT (n, %)	2 (16.7)	8 (80)	0.009*
AAD class IB	0	1 (10%)	0.45
AAD class IC	2 (16.7%)	0	0.48
AAD class II	6 (50%)	10 (100%)	0.02*
AAD class III	1 (8.3%) 0	4 (40%)	0.14
AAD class IV	2 (16.7%)	0	0.48
CCB-DHP	2 (16.7%)	0	0.48
Ranolazine	0	2 (20%)	0.19
ACEI	2 (16.7%)	8 (80%)	0.008*
Digoxin	0	1 (10%)	0.45
Spironolactone	0	1 (10%)	0.45
Multi-electrode catheter	6 (50%)	6 (60%)	0.69

AAD, anti-arrhythmic drugs; ACEI, angiotensin converting enzyme inhibitors; CCB-DHP, calcium channel blockers dihydropyridine class; EF, ejection fraction; ICMP, ischemic cardiomyopathy; LVEDD, left ventricular end-diastolic diameter; SNLV, structurally normal left ventricle; VT, ventricular tachycardia as an indication for the ablation procedure.

The row labeled “Multi-Electrode Catheter” summarizes the number (%) of patients that had APDR data collected using a multi-electrode catheter (either Pentaray 4-4-4; Biosense Webster or LiveWire; Abbott). Values in bold represent p-values less than 0.05 which is the cut-off for statistical significance. *Denotes p-values less than 0.05 which is the cut-off for statistical significance.